Genotype 1 Hepatitis C Virus Envelope Features That Determine Antiviral Response Assessed through Optimal Covariance Networks

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Murray, John M ^a,b   Moenne Loccoz, Rémy ^c   Velay, Aurélie ^d,e   Habersetzer, François ^c,f,g   Doffoël, Michel ^c,f,g   Gut, Jean Pierre ^g   Fofana, Isabel ^f,g   Zeisel, Mirjam B ^f,g   Stoll Keller, Françoise ^f,g,h   Baumert, Thomas F ^c,f,g   Schvoerer, Evelyne ^d,e  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c HÔPITAL CIVIL   (France)

^d UNIVERSITÉ DE LORRAINE   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f INSERM   (France)

^g UNIVERSITÉ DE STRASBOURG   (France)

^h UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GAMMA INTERFERON; RIBAVIRIN;

ARTICLE; CLUSTER ANALYSIS; COVARIANCE; DRUG RESPONSE; ENVELOPE GENE; ENVELOPE GENE E1E2; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; SUSTAINED VIROLOGIC RESPONSE; VIROLOGY; VIRUS ENVELOPE;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; PHYLOGENY; RIBAVIRIN; TREATMENT OUTCOME; VIRAL ENVELOPE PROTEINS;

HEPATITIS C VIRUS;

EID: 84879264532     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067254     Document Type: Article

References (29)

1. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, et al. (2002) Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 99: 15661-15668.
2. Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, et al. (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proceedings of the National Academy of Sciences. 104: 6025-6030.
3. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
4. Wohnsland A, Hofmann WP, Sarrazin C, (2007) Viral Determinants of Resistance to Treatment in Patients with Hepatitis C. Clinical Microbiology Reviews. 20: 23-38.
5. Pawlotsky J-M, (2009) Hepatitis: HCV variability, the immune system and resistance to antiviral drugs. Nat Rev Gastroenterol Hepatol 6: 383-385.
6. Legrand-Abravanel F, Colson P, Leguillou-Guillemette H, Alric L, Ravaux I, et al. (2009) Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. Journal of Medical Virology 81: 2029-2035.
7. Pawlotsky JM, (2011) Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 53: 1742-1751.
8. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM, (2012) Antiviral strategies in hepatitis C virus infection. Journal of Hepatology 56Suppl 1: S88-100.
9. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, et al. (2007) Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132: 667-678.
10. Keck ZY, Li SH, Xia J, von Hahn T, Balfe P, et al. (2009) Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. Journal of Virology 83: 6149-6160.
11. Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, et al. (2010) Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. The Journal of Experimental Medicine 207: 2019-2031.
12. Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, et al. (2012) Mutations That Alter Use of Hepatitis C Virus Cell Entry Factors Mediate Escape From Neutralizing Antibodies. Gastroenterology 143: 223-233.e229.
13. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF, (2011) Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies. Journal of hepatology 54: 566-576.
14. Keck ZY, Op De Beeck A, Hadlock KG, Xia J, Li TK, et al. (2004) Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. Journal of Virology 78: 9224-9232.
15. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MMC, (1999) Inhibition of the Interferon- Inducible Protein Kinase PKR by HCV E2 Protein. Science 285: 107-110.
16. Schvoerer E, Moenne-Loccoz R, Murray JM, Velay A, Turek M, et al. (2013) Hepatitis C Virus Envelope Glycoprotein Signatures Are Associated With Treatment Failure and Modulation of Viral Entry and Neutralization. Journal of Infectious Diseases 207: 1306-1315.
17. Altschuh D, Lesk AM, Bloomer AC, Klug A, (1987) Correlation of co-ordinated amino acid substitutions with function in viruses related to tobacco mosaic virus. Journal of Molecular Biology 193: 693-707.
18. Gobel U, Sander C, Schneider R, Valencia A, (1994) Correlated mutations and residue contacts in proteins. Proteins 18: 309-317.
19. Eyal E, Frenkel-Morgenstern M, Sobolev V, Pietrokovski S, (2007) A pair-to-pair amino acids substitution matrix and its applications for protein structure prediction. Proteins 67: 142-153.
20. Lee B-C, Park K, Kim D, (2008) Analysis of the residue-residue coevolution network and the functionally important residues in proteins. Proteins: Structure, Function, and Bioinformatics 72: 863-872.
21. Aurora R, (2009) Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. The Journal of Clinical Investigation 119: 225-236.
22. Nemhauser GL, Wolsey LA (1988) Integer and combinatorial optimization. New York: Wiley.
23. Hofmann WP, Zeuzem S, Sarrazin C, (2005) Hepatitis C virus-related resistance mechanisms to interferon [alpha]-based antiviral therapy. Journal of Clinical Virology 32: 86-91.
24. Brown RJP, Tarr AW, McClure CP, Juttla VS, Tagiuri N, et al. (2007) Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes. Journal of General Virology 88: 458-469.
25. Krey T, d'Alayer J, Kikuti CM, Saulnier A, Damier-Piolle L, et al. (2010) The Disulfide Bonds in Glycoprotein E2 of Hepatitis C Virus Reveal the Tertiary Organization of the Molecule. PLoS Pathog 6: e1000762.
26. Troesch M, Meunier I, Lapierre P, Lapointe N, Alvarez F, et al. (2006) Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology 352: 357-367.
27. Lara J, Xia G, Purdy M, Khudyakov Y, (2011) Coevolution of the Hepatitis C Virus Polyprotein Sites in Patients on Combined Pegylated Interferon and Ribavirin Therapy. Journal of Virology 85: 3649-3663.
28. Dubois F, Desenclos J, Mariotte N, Goudeau A, The Collaborative Study G, (1997) Hepatitis C in a French population-based survey, 1994: Seroprevalence, frequency of viremia, genotype distribution, and risk factors. Hepatology 25: 1490-1496.
29. Keck ZY, Olson O, Gal-Tanamy M, Xia J, Patel AH, et al. (2008) A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. Journal of Virology 82: 6067-6072.